Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates

Manhattan ResearchManhattan Research, a leader in syndicated research and marketing services for the health and pharmaceutical industry, today revealed the top pharmaceutical branded product websites ranked by offline requests by U.S. adult consumers. The product site rankings are based on the comprehensive online consumer research study with 5,112 U.S. adults titled ePharma Consumer® v7.0: The Future of Integrated DTC Marketing. In addition to the top product site rankings, the study provides in-depth data on more than 200 leading pharmaceutical product sites including site satisfaction, site search rationales, tools and features desired on product sites, and a wide range of consumer actions taken afterwards.

"Having the most unique visitors is no longer the ultimate goal of a successful pharmaceutical product site," says Mark Bard, president of Manhattan Research. He continues, “Brand teams and agencies are being challenged to demonstrate the economic and strategic value created by these online destinations – beyond the raw number of visitors or page views. After all, if a site is all traffic and no action then what is the strategic value of the site?"

Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests

1. Chantix
2. Cialis
3. Viagra
4. Aciphex
5. Ambien CR
6. Levitra
7. Lamisil
8. Lunesta
9. Wellbutrin XL
10. Ortho Evra

Source: ePharma Consumer® v7.0, Manhattan Research, LLC

To learn more about consumer segments of pharmaceutical information seekers, contact Manhattan Research by visiting www.manhattanresearch.com/ePC.htm.

Some of the additional product sites researched within ePharma Consumer® v7.0 include the following: Abilify, Actonel, Advair, Aranesp, Aricept, Avandia, Boniva, Botox, Caduet, Concerta, Crestor, Cymbalta, Depakote, Depo-Provera, Detrol LA, Effexor XR, Enbrel, Flomax, Flonase, Flovent, Fosamax, Gardasil, Glucophage XR, Humira, Humulin, Imitrex, Lantus, Lexapro, Lipitor, Nasacort, Nasonex, Neulasta, Neurontin, Nexium, Norvasc, NuvaRing, Ortho Tri-Cyclen Lo, Paxil, Plavix, Pravachol, Prevacid, Protonix, Provigil, Pulmicort, Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL, Tricor, Valtrex, Vytorin, Yasmin, Yaz, Zocor, Zoloft, Zomig, Zyprexa and Zyrtec.

Please visit www.manhattanresearch.com/ePC.htm to download the ePharma Consumer® product brochure, request subscription information, and to listen to two audio presentations summarizing highlights from the research.

About Manhattan Research
ePharma Consumer® v7.0 is a syndicated multi-client study and advisory service focused on key research topics and trends impacting online U.S. consumers seeking pharmaceutical information. The study was fielded in December 2007 among 5,112 U.S. adult consumers. In addition to ePharma Consumer®, Manhattan Research conducts five additional research studies annually among consumers and physicians in the United States and in Europe: Cybercitizen® Health US, Cybercitizen® Health Europe, Taking the Pulse® US, Taking the Pulse® Europe, and ePharma Physician®. Each study serves a unique purpose and focuses on specific aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analyses among more than 50 consumer therapeutic segments and 25 physician specialist segments.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...